Impairment of the metabolism of dipyrone in asymptomatic carriers of the hepatitis B virus

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 1, 1997, Pages 6-14

  Levy, Micha ^a   Leibowich, Igal ^a   Zylber Katz, Ester ^a   Ilan, Yaron ^a   Granit, Liora ^a   Sviri, Sigal ^a   Caraco, Yoseph ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRONE; DRUG METABOLITE;

ACETYLATOR PHENOTYPE; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; HEPATITIS B VIRUS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; VIRUS HEPATITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CARRIER STATE; DIPYRONE; FEMALE; HALF-LIFE; HEPATITIS B VIRUS; HUMANS; MALE;

EID: 0030852015     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90145-4     Document Type: Article

References (29)

1. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21:42-69.
2. Levy M, Blum A, Caraco Y, Granit L, Zylber-Katz E. The pharmacokinetics of dipyrone product 4-methylaminoantipyrine in patients with liver cirrhosis. Drug Invest 1992;4:219-26.
3. Zylber-Katz E, Caraco Y, Granit L, Levy M. Dipyrone metabolism in liver disease. Clin Pharmacol Ther 1995;58:198-209.
4. Bass NM, Williams RL. Guide to drug dosage in hepatic disease. Clin Pharmacokinet 1988;15:396-420.
5. Burnett DA, Barak AJ, Tuma DJ, Sorrell MF. Altered elimination of antipyrine in patients with acute viral hepatitis. Gut 1976;17:341-4.
6. Narang AP, Datta DV, Nath N, Mathur VS. Impairment of hepatic drug metabolism in patients with acute viral hepatitis. Eur J Drug Metab Pharmacokinet 1982;7:255-8.
7. Chang KC, Bell TD, Lauer BA, Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978;1:1132-3.
8. Kraemer MJ, Furukawa CT, Koup JR, Shapiro GG, Pierson WE, Bierman CW. Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982;69:476-80.
9. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993;53:529-35.
10. Van der Ven AJAM, Vree TB, Van Ewijk-Beneken, Kolmer EWJ, Koopmans PP, Van der Meer JWM. Urinary recovery and kinetics of sulfamethoxazole and its metabolites in HIV seropositive patients and healthy volunteers after a single oral dose of sulfamethoxazole. Br J Clin Pharmacol 1995;39:621-5.
11. Levy M. The combined effect of viruses and drugs in drug-induced diseases. Med Hypotheses 1984;14: 293-6.
12. Renton KW, Knickle LC. Regulation of hepatic cytochrome P-450 during infectious disease. Can J Physiol Pharmacol 1989;68:777-81.
13. Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995;28:216-34.
14. Schulster LM, Hollinger FB, Dreesman GR, Melnick JL. Immunological and biophysical alteration of hepatitis B virus antigens. Appl Environ Microbiol 1981; 42:762-7.
15. Levy M, Flusser D, Zylber-Katz E, Granit L. Plasma kinetics of dipyrone metabolites in rapid and slow acetylators. Eur J Clin Pharmacol 1984;27:453-8.
16. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
17. Zylber-Katz E, Granit L, Drayer DE, Levy M. Simultaneous determinations of dipyrone metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1984;305:477-84.
18. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989;40:439-74.
19. Villeneuve JP, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994;106:1000-5.
20. Dragosics B, Ference P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987;7:302-6.
21. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology 1987;7:758-63.
22. Loriot MA, Marcellin P, Bismuth E, Martinot-Peignoux M, Boyer N, Degott C, et al. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 1992;15:32-6.
23. Clark CJ, Boyd G. Theophylline pharmacokinetics during respiratory viral infection [letter]. Lancet 1979;1:492.
24. Tett S, Moore S, Ray J. Pharmacokinetics and bioavailability fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob Agents Chemother 1995;39: 1835-41.
25. Delomenie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier L, Jacoz-Aigrain E, et al. N-Acétylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 1994;38:581-2.
26. Chu CM, Sheen IS, Yeh CT, Hsieh SY, Tsai SL, Liaw YF. Serum levels of interferon-α and -γ in acute and chronic hepatitis B virus infection. Dig Dis Sci 1995; 40:2107-12.
27. Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986;22: 610-2.
28. Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987;2:939-41.
29. Volz M, Fehlhaben HW, Siebenlist F. Biotransformation of metamizole [abstract]. Presented at the Fifth European ISSX Meeting; Paris, France, September 26-29, 1993:70.